Haridwar Today

DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Pulmonary Fibrosis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Idiopathic Pulmonary Fibrosis Pipeline? @ https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight

Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report

• On June 01, 2026- Contineum Therapeutics initiated a phase 2 study to evaluate the efficacy, safety, tolerability, and PK of PIPE-791 in subjects with a diagnosis of Idiopathic Pulmonary Fibrosis with or without background treatment. The treatment period is 26 weeks and full study duration is up to 36 weeks including Screening and Follow-Up. Approximately 324 subjects will be enrolled into one of three treatment arms, PIPE-791 Dose A, PIPE-791 Dose B, or placebo.
• On May 27, 2026- Boehringer Ingelheim conducted a phase IIa study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or equal to 45% of the predicted value and fibrosis of 20% or more confirmed by a high-resolution computed tomography (HRCT) scan. The purpose of this study is to find out if a medicine called BI 765423 can improve lung function in people with IPF. The study will compare BI 765423 with a placebo to see if there is a difference in lung capacity after 3 months of treatment and will also look at changes in certain markers related to lung health.
• On May 13, 2026- Dragonboat Biopharmaceutical Company Limited initiated a Phase II clinical study to evaluate the efficacy and safety of BC006 over a 24-week treatment period in patients with idiopathic pulmonary fibrosis (IPF). The study consists of two phases: an open-label safety run-in phase and a double-blind, randomized, placebo-controlled phase.
• On May 07, 2026- Rein Therapeutics announced a research study is to evaluate LTI-03 including: its safety, whether it causes side effects, whether it improves lung scarring, and whether it improves IPF symptoms. LTI-03 will be compared to placebo in patients diagnosed with IPF within the last 5 years. Patients on a stable dose of nintedanib, pirfenidone, or nerandomilast (if available by prescription) may participate.
• On May 01, 2026- Vicore Pharma AB conducted a ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF.
• DelveInsight’s Idiopathic Pulmonary Fibrosis Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Idiopathic Pulmonary Fibrosis treatment.
• The leading Idiopathic Pulmonary Fibrosis Companies such as Bristol-Myers Squibb, Sunshine Lake Pharma Co., Ltd., Guangzhou JOYO Pharma Co., Ltd., Genetech, Inc., Tvardi Therapeutics, Incorporated, GRI Bio Operations, Inc., Shanghai Synvida Biotechnology Co., Ltd., SPARK Biopharma, Redx Pharma Ltd., PureTech, Trevi Therapeutics, Mediar Therapeutics, Melius Pharma AB, Rein Therapeutics, Cumberland Pharmaceuticals, Haisco Pharmaceutical Group Co., Ltd., GlaxoSmithKline, Endeavor Biomedicines, Inc., Daewoong Pharmaceutical Co. LTD., Calluna Pharma AS, Vicore Pharma AB, Boehringer Ingelheim, Syndax Pharmaceuticals, AstraZeneca, Arrowhead Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co., Ltd., Shenzhen Resproly Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., Agomab Spain S.L., Pulmongene Ltd and others.
• Promising Idiopathic Pulmonary Fibrosis Pipeline Therapies such as Pirfenidone, Deupirfenidone, SC1011, TTI-101, Pamrevlumab, PLN-74809, GSK3915393, and others.

Want to know which companies are leading innovation in Idiopathic Pulmonary Fibrosis? @ Idiopathic Pulmonary Fibrosis Clinical Trials Assessment

The Idiopathic Pulmonary Fibrosis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Idiopathic Pulmonary Fibrosis Pipeline Report also highlights the unmet needs with respect to the Idiopathic Pulmonary Fibrosis.

Idiopathic Pulmonary Fibrosis Overview

Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as ‘Diffuse Parenchymal Lung Diseases,’ which is characterized by a broader umbrella of ‘Interstitial Lung Diseases (IDLs).

Idiopathic Pulmonary Fibrosis Emerging Drugs Profile

• BMS-986278: Bristol-Myers Squibb

Admilparant (BMS-986278) is a potential first-in-class, oral, small molecule lysophosphatidic acid receptor 1 (LPA1) antagonist currently being evaluated as a novel antifibrotic treatment for patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Increased LPA levels and activation of LPA1 are involved in the pathogenesis of pulmonary fibrosis. A preclinical in vitro and in vivo study found that antagonizing LPA1 may be beneficial in treating lung injury and fibrosis. Currently, the drug is in the Phase III stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

• ENV-101: Endeavor BioMedicine

ENV-101 (Endeavor BioMedicine) is an investigational small-molecule therapy being developed by Endeavor BioMedicine for fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). It is designed to selectively inhibit pathways involved in fibrosis progression, aiming to reduce excessive tissue scarring and preserve lung function. The drug is currently in early clinical development, with studies focused on evaluating its safety, tolerability, and anti-fibrotic activity. Preclinical findings have shown potential to modulate key drivers of fibrosis, supporting its advancement into human trials. Overall, ENV-101 represents a targeted approach that could offer improved disease control compared to existing symptomatic treatments for fibrotic lung disorders. Currently, the drug is in the Phase II stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

• AZD8965: AstraZeneca

AZD8965 (AstraZeneca) is an investigational small-molecule therapy being developed by AstraZeneca for idiopathic pulmonary fibrosis (IPF). It functions as an arginase (ARG1/ARG2) inhibitor, targeting metabolic pathways linked to fibrosis progression. The drug is currently in Phase I clinical development, with ongoing studies evaluating its safety, tolerability, and pharmacokinetics in healthy participants. By modulating arginase activity, AZD8965 aims to reduce fibrotic remodeling and inflammation, representing a novel mechanism compared to existing IPF therapies. If successful, it could provide a new targeted treatment approach for fibrotic lung diseases. Currently, the drug is in the Phase I stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

If you’re tracking ongoing Idiopathic Pulmonary Fibrosis Clinical trials, this press release is a must-read @ Idiopathic Pulmonary Fibrosis Treatment Drugs

The Idiopathic Pulmonary Fibrosis Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Pulmonary Fibrosis Treatment.
• Idiopathic Pulmonary Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Idiopathic Pulmonary Fibrosis market.

Idiopathic Pulmonary Fibrosis Companies

Bristol-Myers Squibb, Sunshine Lake Pharma Co., Ltd., Guangzhou JOYO Pharma Co., Ltd., Genetech, Inc., Tvardi Therapeutics, Incorporated, GRI Bio Operations, Inc., Shanghai Synvida Biotechnology Co., Ltd., SPARK Biopharma, Redx Pharma Ltd., PureTech, Trevi Therapeutics, Mediar Therapeutics, Melius Pharma AB, Rein Therapeutics, Cumberland Pharmaceuticals, Haisco Pharmaceutical Group Co., Ltd., GlaxoSmithKline, Endeavor Biomedicines, Inc., Daewoong Pharmaceutical Co. LTD., Calluna Pharma AS, Vicore Pharma AB, Boehringer Ingelheim, Syndax Pharmaceuticals, AstraZeneca, Arrowhead Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co., Ltd., Shenzhen Resproly Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., Agomab Spain S.L., Pulmongene Ltd and others.

Idiopathic Pulmonary Fibrosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

The Idiopathic Pulmonary Fibrosis Pipeline Report covers it all @ Idiopathic Pulmonary Fibrosis Market Drivers and Barriers, and Future Perspectives

Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report

• Coverage- Global
• Idiopathic Pulmonary Fibrosis Companies- Bristol-Myers Squibb, Sunshine Lake Pharma Co., Ltd., Guangzhou JOYO Pharma Co., Ltd., Genetech, Inc., Tvardi Therapeutics, Incorporated, GRI Bio Operations, Inc., Shanghai Synvida Biotechnology Co., Ltd., SPARK Biopharma, Redx Pharma Ltd., PureTech, Trevi Therapeutics, Mediar Therapeutics, Melius Pharma AB, Rein Therapeutics, Cumberland Pharmaceuticals, Haisco Pharmaceutical Group Co., Ltd., GlaxoSmithKline, Endeavor Biomedicines, Inc., Daewoong Pharmaceutical Co. LTD., Calluna Pharma AS, Vicore Pharma AB, Boehringer Ingelheim, Syndax Pharmaceuticals, AstraZeneca, Arrowhead Pharmaceuticals, Wuhan Optics Valley Vcanbiopharma Co., Ltd., Shenzhen Resproly Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., Agomab Spain S.L., Pulmongene Ltd and others.
• Idiopathic Pulmonary Fibrosis Pipeline Therapies- Pirfenidone, Deupirfenidone, SC1011, TTI-101, Pamrevlumab, PLN-74809, GSK3915393, and others.
• Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Idiopathic Pulmonary Fibrosis Treatment landscape in this detailed analysis @ Idiopathic Pulmonary Fibrosis Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Idiopathic Pulmonary Fibrosis: Overview
4. Pipeline Therapeutics
5. Therapeutics Assessment
6. Idiopathic Pulmonary Fibrosis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. BMS-986278: Bristol-Myers Squibb
9. Mid Stage Products (Phase II)
10. ENV-101: Endeavor BioMedicine
11. Early Stage Products (Phase I)
12. AZD8965 AstraZeneca
13. Preclinical and Discovery Stage Products
14. Inactive Products
15. Idiopathic Pulmonary Fibrosis Key Companies
16. Idiopathic Pulmonary Fibrosis Key Products
17. Idiopathic Pulmonary Fibrosis- Unmet Needs
18. Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
19. Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
20. Idiopathic Pulmonary Fibrosis Analyst Views
21. Idiopathic Pulmonary Fibrosis Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight